Chennai: Caplin Point Laboratories Limited has announced the acquisition of 10 approved ANDAs from an unnamed multinational generic manufacturer as the company looks to boost its portfolio in the injectable and ophthalmic product range. For Caplin Point, this acquisition means it has the approval from the US FDA to launch 10 generic drugs boosting its portfolio through its subsidiaries Caplin Steriles Limited (CSL) and CAplin One Labs Limited (COL).
These ANDAs offer Caplin Point access to a niche addressable market worth approximately $473.2 million, especially in the ophthalmic segment. These products are expected to boost Caplin Point’s market share and visibility, especially in the eye care therapy and injectible markets.
“The U.S. market remains a key growth engine for the Company, and this acquisition meaningfully accelerates our strategy by expanding and strengthening our portfolio in the region. The acquired portfolio also includes select oncology injectables, which will be transferred to and commercialized from our new dedicated oncology facility in Kakkalur. In addition, we intend to progressively extend these products to key non-U.S. markets, including Mexico, Canada, the European Union, and Brazil.” Mr. C.C. Paarthipan, Chairman, Caplin Point Laboratories, said in a press release.
Caplin Point remains a fast-growing pharmaceutical company targeted towards emerging markets in Latin America and Africa. Its manufacturing facilities are approved by various global agencies, including the US FDA and others. So far, it has filed 53 ANDAs on its own, and is looking to file approvals for multiple products across countries like Australia, Canada, Mexico, Chile, UAE and South Africa. So far, Caplin Point has already acquired 5 out of the 10 ANDAs for the current acquisition.
